Cladribine

Generic Name: Cladribine

Brand Names: Litak, Mavenclad

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂ClN_₅O_₃

CAS Number: 4291-63-8

Unique Ingredient Identifier: 47M74X9YT5

Background: An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.

Indication: For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.

Associated Conditions: Chronic Lymphocytic Leukemia, Cutaneous T-Cell Lymphoma (CTCL), Hairy Cell Leukemia (HCL), Non-Hodgkin's Lymphomas, Active confirmed by clinical features, confirmed by imaging features relapsing multiple sclerosis (MS)

Associated Therapies: -

Clinical Trials

Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia

Phase 2

Conditions: Acute Myeloid Leukemia
Relapse Leukemia

Interventions: Drug: Cladribine
Drug: G-CSF
Drug: Aclarubicin
Drug: Cytarabine

First Posted Date: 2017-06-09

Last Posted Date: 2019-08-20

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 48

Registration Number: NCT03181815

Locations: 🇨🇳
Liang Wang, Guangzhou, Guangdong, China

Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell Lymphoma

Phase 2

Conditions: Lymphoma

Interventions: Drug: Chidamide
Drug: Cladribine
Drug: gemcitabine
Drug: Busulfan
Procedure: Autologous hematopoietic stem cell transplantation

First Posted Date: 2017-05-12

Last Posted Date: 2018-07-18

Lead Sponsor: Sichuan University

Target Recruit Count: 93

Registration Number: NCT03151876

Locations: 🇨🇳
Shan Xi Da Yi Hospital, Taiyuan, Shanxi, China
🇨🇳
General Hospital of Lanzhou military command, Lanzhou, Gansu, China
🇨🇳
Peking university third hospital, Beijing, Beijing, China

and more 15 locations

Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm

Phase 2

Completed

Conditions: Acute Leukemia of Ambiguous Lineage
Myeloid Neoplasm
Acute Myeloid Leukemia

Interventions: Drug: Cladribine
Drug: Cytarabine
Biological: Granulocyte Colony-Stimulating Factor
Drug: Mitoxantrone Hydrochloride
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2017-01-06

Last Posted Date: 2022-03-08

Lead Sponsor: University of Washington

Target Recruit Count: 50

Registration Number: NCT03012672

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS

Phase 1

Completed

Conditions: Mixed Phenotype Acute Leukemia
Previously Treated Myelodysplastic Syndrome
Recurrent Adult Acute Myeloid Leukemia
Recurrent High Risk Myelodysplastic Syndrome
Refractory High Risk Myelodysplastic Syndrome
Refractory Acute Myeloid Leukemia
Untreated Adult Acute Myeloid Leukemia

Interventions: Drug: Cladribine
Drug: Cytarabine
Drug: Decitabine
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Drug: Mitoxantrone Hydrochloride

First Posted Date: 2016-09-30

Last Posted Date: 2020-03-17

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 28

Registration Number: NCT02921061

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms

Phase 2

Completed

Conditions: High Grade Malignant Neoplasm
Previously Treated Myelodysplastic Syndrome
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
Myelodysplastic Syndrome With Excess Blasts-2
Myeloid Neoplasm
Blasts 10 Percent or More of Bone Marrow Nucleated Cells
Chronic Myelomonocytic Leukemia-2
Myelodysplastic Syndrome

Interventions: Drug: Cladribine
Drug: Cyclosporine
Drug: Cytarabine
Biological: Filgrastim
Drug: Fludarabine Phosphate
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Drug: Mitoxantrone Hydrochloride
Drug: Mycophenolate Mofetil
Other: Questionnaire Administration
Drug: Sirolimus
Radiation: Total-Body Irradiation
Drug: Melphalan Hydrochloride

First Posted Date: 2016-04-29

Last Posted Date: 2021-11-08

Lead Sponsor: University of Washington

Target Recruit Count: 30

Registration Number: NCT02756572

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Myelodysplastic Syndrome
Myeloproliferative Neoplasm
Acute Myeloid Leukemia
de Novo Myelodysplastic Syndrome
Acute Biphenotypic Leukemia

Interventions: Drug: Cladribine
Drug: Cytarabine
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Drug: Mitoxantrone
Drug: Sorafenib

First Posted Date: 2016-04-05

Last Posted Date: 2023-07-05

Lead Sponsor: University of Washington

Target Recruit Count: 84

Registration Number: NCT02728050

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Selinexor
Drug: Cladribine
Drug: G-CSF
Drug: Cytarabine
Procedure: Bone marrow biopsy

First Posted Date: 2015-04-15

Last Posted Date: 2020-03-13

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 40

Registration Number: NCT02416908

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Busulfan
Drug: Cladribine
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Pharmacological Study
Drug: Venetoclax

First Posted Date: 2014-09-26

Last Posted Date: 2024-11-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 116

Registration Number: NCT02250937

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

Phase 2

Recruiting

Conditions: Langerhans Cell Histiocytosis

Interventions: Procedure: hematopoietic stem cell transplantation (RIC-HSCT)
Drug: Prednisone
Drug: 2-chlorodeoxyadenosine
Drug: Vinblastine
Biological: Intravenous immunoglobulin
Drug: mercaptopurine
Drug: INDOMETHACIN
Drug: Methotrexate
Drug: Cytosine Arabinoside

First Posted Date: 2014-07-31

Last Posted Date: 2023-03-23

Lead Sponsor: North American Consortium for Histiocytosis

Target Recruit Count: 1400

Registration Number: NCT02205762

Locations: 🇺🇸
Children's Medical Center Dallas, UT Southwestern, Dallas, Texas, United States
🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 35 locations

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients with Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Phase 2

Recruiting

Conditions: Acute Biphenotypic Leukemia
Acute Myeloid Leukemia
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Blasts 10 Percent or More of Bone Marrow Nucleated Cells
Blasts 10 Percent or More of Peripheral Blood White Cells
De Novo Myelodysplastic Syndrome
Myelodysplastic Syndrome
Previously Treated Myelodysplastic Syndrome
Recurrent Acute Myeloid Leukemia
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Interventions: Drug: Cladribine
Drug: Cytarabine
Drug: Gilteritinib
Drug: Idarubicin
Other: Laboratory Biomarker Analysis
Drug: Midostaurin
Drug: Venetoclax

First Posted Date: 2014-04-16

Last Posted Date: 2024-12-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 508

Registration Number: NCT02115295

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy